title: Roxithromycin and lower respiratory tract infections.
authors.forename: W G
authors.initials: WG
authors.lastname: Scott
authors.forename: B C
authors.initials: BC
authors.lastname: Cooper
authors.forename: H M
authors.initials: HM
authors.lastname: Scott
authors.forename: N C
authors.initials: NC
authors.lastname: Karalus
authors.forename: J
authors.initials: J
authors.lastname: Garrett
authors.forename: S D
authors.initials: SD
authors.lastname: Lang
mesh_terms: D000328:Adult; D000658:Amoxicillin / Q000191:economics / Q000627:therapeutic use; D019980:Amoxicillin-Potassium Clavulanate Combination; D002969:Clavulanic Acids / Q000191:economics / Q000627:therapeutic use; D017714:Community-Acquired Infections / Q000188:drug therapy*; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D004359:Drug Therapy, Combination / Q000627:therapeutic use*; D006801:Humans; D009520:New Zealand; D012141:Respiratory Tract Infections / Q000188:drug therapy*; D015575:Roxithromycin / Q000191:economics / Q000627:therapeutic use*
chemical_list: D002969:Clavulanic Acids; D015575:Roxithromycin; D019980:Amoxicillin-Potassium Clavulanate Combination; D000658:Amoxicillin